REVVITY, INC.

Revvity provides health science technologies, expertise, and integrated workflow solutions bridging research, clinical discovery, and medical care. The company operates across two core segments: Life Sciences and Diagnostics. Its Life Sciences division delivers reagents, automated liquid handlers, imaging instruments, detection platforms, and research informatics designed to optimize drug development, genomics, and cellular analysis. Its Diagnostics segment supplies analytical instruments, diagnostic assays, screening kits, and laboratory data management software specializing in prenatal and newborn screening, immunodiagnostics, and infectious disease detection. Revvity serves pharmaceutical and biotechnology corporations, contract research organizations, academic and governmental research institutions, hospitals, clinical laboratories, and healthcare professionals.

Headquartered in Waltham, Massachusetts, the company conducts its commercial operations globally, marketing products and services across more than 160 countries. Its operational infrastructure includes a worldwide network of specialized genomic testing laboratories located in the United States, China, the United Kingdom, and India. Revvity maintains an international workforce of approximately 11,000 employees supporting its healthcare and diagnostic capabilities.

Summary of the business section of Revvity's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 28, 2025, we employed approximately 11,000 employees on a worldwide basis.”